StockNow
Calendar
Log in
U.S. Markets

AbbVie (ABBV) announces that the US FDA has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan in colorectal cancer and non-small cell lung cancer

StockNow breaking-news AI analysis

The supplied headline reports two FDA Breakthrough Therapy Designations for telisotuzumab adizutecan; the record contains no article body or further details.

1 stocks
ABBVABBVIE INC.$267.58Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Iranian Army spokesperson says Iran will launch pre-emptive attacks if needed and used new offensive and defensive equipment during the 40-day war, Fars reports

Politics

Senior Iranian official says US VP Vance's comments on Iran's nuclear programme are American "ideas and requests"; US ideas are at opposite with Iran's demands

Geopolitics

IRGC commander adviser Naqdi says the Strait of Hormuz remains closed and under full control of Iran’s armed forces until Iran’s demands are met, while illegal routes used for oil smuggling will soon be blocked, Fars reports